Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 06/01/23
End: 02/15/28
Due: 02/15/29
Phase: N/A
Priority: Normal
Start: 06/30/22
End: 09/30/25
Due: 09/30/26
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT) | NCT05607550 | ArriVent BioPharma, Inc. | user2@example.com | None | 2023-06-01 | 2028-02-15 | 2029-02-15 | - | - | 2025-07-14 |
| Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations | NCT05364073 | ArriVent BioPharma, Inc. | user2@example.com | None | 2022-06-30 | 2025-09-30 | 2026-09-30 | - | - | 2025-07-14 |